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CASE STUDY
Frequency of G6PD Mediterranean 
in individuals with and without malaria 
in Southern Pakistan
Bushra Moiz1* , Haroon Muhammad Arshad2, Ahmed Raheem1, Hasan Hayat3, Najia Karim Ghanchi1 
and M. Asim Beg1
Abstract 
Background: Pakistan has an estimated annual burden of 1.5 million malaria cases. The current situation calls for an 
effective malaria control and eradication programme in this country. Currently, primaquine is an attractive option for 
eliminating reservoirs of Plasmodium vivax hypnozoites and killing gametocytes of Plasmodium falciparum. However, 
this drug causes haemolysis in individuals who are glucose-6-phosphate (G6PD) deficient. It is important to map 
G6PD deficiency and malaria distribution in Pakistan to design an effective malaria eradication regimen. Frequency 
of G6PD deficiency (G6PDd) in malaria patients has not been reported from Pakistan in any meaningful way. The 
purpose of this study was to evaluate the frequency of G6PD c.563C>T (G6PD Mediterranean) in male individuals with 
and without falciparum malaria.
Methods: Two hundred and ten archived DNA samples from males (110 from falciparum malaria patients and 100 
from healthy individuals) were utilized in this study. Healthy blood donors were selected based on stringent pre-
defined criteria. Patients were confirmed for malaria parasites on microscopy and or immune chromatographic assay 
detecting P. falciparum histidine-rich protein 2. Parasitaemia was also computed. DNA samples were tested for G6PD 
c.563C>T mutation through PCR–RFLP according to the previously defined protocol and its allelic frequency was 
computed.
Results: G6PD c.563C>T was observed in four of 110 patients with falciparum malaria and in two of 100 healthy 
donors. Mean (± SD) haemoglobin, median (IQR) platelet and median (IQR) parasite count in G6PD-deficient malaria-
patients were 8.9 ± 0.9 g/dL, 124 × 109/L (IQR 32, 171) and 57,920/μL of blood (IQR 12,920, 540,000) respectively.
Conclusions: Cumulative allelic frequency for G6PD 563c.C>T was 0.0285 detected in 6 of 210 X-chromosomes in 
Southern Pakistan. Frequency for this G6PD allele was 0.0364 in malaria-patients and 0.0200 in healthy individuals. 
Large studies including females are needed to elucidate the true burden of G6PDd in malaria-endemic areas. The 
information will enable local health policy makers to design effective strategies for eliminating malaria form this 
region.
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Background
With an estimated load of 1.5 million malaria cases each 
year, Pakistan is among seven countries of the WHO 
Eastern Mediterranean Region sharing 95% of the total 
regional malaria burden [1]. Malaria with Plasmodium 
vivax is endemic and more common (88%) in this coun-
try, while malaria with Plasmodium falciparum is seen 
only during rainy seasons or post rain and accounts for 
12% of the malaria burden [2]. The current situation 
calls for an effective malaria control and eradication 
programme in Pakistan. Currently, the only drug that is 
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available for malaria eradication is primaquine (an 8-ami-
noquinoline) which kills P. vivax hypnozoites [3] and P. 
falciparum gametocytes [4]. However, the administration 
of primaquine may be dangerous in individuals who are 
glucose-6-phosphate dehydrogenase (G6PD) deficient.
G6PD is a pentose pathway enzyme which catalyzes the 
rate limiting step in the reduction of nicotine amide ade-
nine dinucleotide phosphate (NADP). Reduced NADP 
is critical for eradicating free radicals from the cells and 
maintaining their viability. Therefore, generally asymp-
tomatic, G6PD-deficient individuals are at risk of drug-, 
food- or infection-induced acute haemolytic anaemia. 
Because the G6PD gene is located on the X-chromosome, 
the prevalence of G6PD in males is higher than that of 
females. Interestingly, global distribution of G6PD defi-
ciency (G6PDd) matches that of past and present malaria 
[5], suggesting a genetic advantage regarding malaria 
risk. For example, in Africa, G6PD A-type offers relative 
protection against falciparum malaria in hemizygous 
males and to some extent in heterozygous females [6]. 
Similarly, G6PD Mediterranean (G6PD-Med)—a variant 
common in Asian countries confers immunity against 
vivax malaria [7] in hemizygous males.
Previous work has shown that G6PD deficiency 
(G6PDd) is widely prevalent in Northern Pakistan with 
a frequency ranging from 2 to 8% in various ethnic 
groups [8]. Moreover, G6PD-Med, is the most common 
G6PD variant in Pakistan [9]. Ashley et  al. reported life 
threatening haemolysis on primaquine administration 
in individuals carrying G6PD-Med [10]. This indicates 
that primaquine administration for malaria eradication 
requires mandatory G6PD testing in Pakistan. Since this 
test is not widely available, malaria will continue to be an 
economic burden for the country.
There is limited information for G6PD-malaria interac-
tion in Pakistan raising several research questions: What 
is the prevalence of G6PDd in Southern Pakistan? Does 
G6PD-Med protect hemizygous males and heterozygous 
or homozygous females from P. falciparum? To respond 
to these basic questions, large-scale studies are needed. 
The present study was aimed in determining allelic fre-
quency of G6PD c.563C>T in male individuals with or 
without malaria by using archived DNA samples. This 
small-scale study is anticipated to become a basis for 
larger studies in evaluating the true burden of G6PDd 
before planning mass primaquine therapy.
Methods
Setting
This was a descriptive study conducted in 2013 at a ter-
tiary care academic institute, Aga Khan University Hospi-
tal (AKUH), Karachi, Pakistan. Karachi is the largest city 
of Pakistan and is the residence to several ethno-lingual 
groups from all over the country. Muhajirs (emigrants 
from India) constitute 50% of its population, while Pash-
tuns are the second largest group. Other ethnic groups 
include Sindhis, Punjabis, Bengalis, Anglo-Indians, Parsi 
and Catholics. AKUH because of its location caters 
mostly Karachites. Therefore, it can be anticipated that 
ethnic background of individuals visiting AKUH or its 
blood bank will be homogenous. This is more rightly so, 
as blood bank works on the principle of exchange dona-
tions thereby prompting relatives of admitted patients 
to donate blood. Approximately 40,000 subjects donate 
blood annually at AKUH blood bank of which 99% 
are male donors. The total number of admissions with 
malaria in AKUH between January 2009 and Decem-
ber 2011 was 365 [11] with estimated annual admis-
sions of 122 patients with malaria. Clinical laboratories 
at Aga Khan University received over 15,000 microscopy 
requests for malarial parasites and subsequently report 
approximately 1800 positive cases each year.
Subjects
Selection of participants
Two hundred and ten archived DNA samples were uti-
lized in the study. This included 110 males who were 
infected with falciparum malaria during 2006–2007 and 
100 healthy males who donated blood at AKUH dur-
ing the same time period. Random sample identification 
technique was used to select patients from a large pool 
of archived DNAs. The focus was to determine G6PDd 
allelic frequency in males who were infected with falcipa-
rum malaria (less common malaria in Pakistan) for which 
we had limited archived samples in AKUH DNA bank. 
EDTA blood sample was collected at the time patient 
presented with malaria, DNA extracted and archived 
at −  80  °C in the research laboratory for future usage. 
Healthy blood donors were selected based on stringent 
pre-defined criteria for blood donation such as no history 
of malaria in past 3 years. G6PD deficiency is an x-linked 
disorder and mainly affects males, therefore, only males 
were included in this study. Moreover, national data for 
G6PDd was available for males predominantly. In addi-
tion, there is a preponderance of male blood donors in 
Pakistan—the control group in this study. Female patients 
and all other patients suffering from vivax malaria were 
excluded.
Malaria diagnosis
For blood donors, ICT malaria test was used for screen-
ing malaria. Patients were routinely diagnosed on 
microscopy (of thick and thin films) and or immune chro-
matographic assay (ICT) for P. falciparum histidine rich 
protein2 (HRP2). Briefly, thick blood films were air dried 
and dipped in water to remove haemolyzed red cells. 
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Slides were then stained with 4–5% Giemsa with phos-
phate buffer saline (pH 7.2) for 25  min and then rinsed 
with tap water. Thick films were examined microscopi-
cally under high power field (100× oil immersion lens) 
for parasitized erythrocytes against 200 white blood cells. 
Parasite density was estimated on thick film assuming a 
standard value of 8000 white blood cells per microlitre of 
blood. Parasitaemia was calculated as follows:
Number of parasites  =  Total parasite counted  ×  200 
white cells/No of white cells/µL of blood. Thin peripheral 
smears were stained with Leishman’s stain and reviewed 
at 40× and 100× objectives.
Clinical details
Medical charts were reviewed for various clinical (res-
piratory and nervous system manifestations) and labora-
tory features (complete blood count, parasitaemia, liver 
function tests, serum creatinine and electrolytes) were 
retrieved from the computerized laboratory data system. 
Duration of hospital stay was also determined. Patients 
were divided into paediatric and adult groups and the cut 
off was ≤ 17 and > 17 years, respectively, as per institu-
tional policy.
Mutational analysis
Archived DNA samples from malaria patients (n = 110) 
and blood donors (n  =  100) were tested for G6PD 
c.563C>T mutation through previously defined protocol 
[9]. Other reported variants like G6PD Chatham were 
not studied as the study was focused on determining rela-
tion between G6PD-Med (predominant and severe form) 
and P. falciparum (having high morbidity and mortality).
Ethical concerns
Ethical approval for this study was granted by The Aga 
Khan University Ethical Review Committee (#509-Pat/
ERC-06). Informed consent was taken from blood donors 
and malaria patients for genotyping. Re-coding was done 
to assure anonymity of the subjects.
Data analysis
Data was entered in Microsoft Excel sheet and trans-
ferred to SPSS version 22 (IBM Statistic data, USA) for 
statistical analysis. Frequency was calculated for age and 
G6PD variant. Descriptive analysis (mean  ±  SD with 
range) was computed for quantitative data with normal 
distribution and median and inter-quartile range (IQR) 
for skewed data. Laboratory parameters were com-
pared with respect to age group and the threshold of 
significance was below 0.05. G6PD allele frequency was 
computed as number of affected males divided by total 
number of males.
Results
Demographic findings
One hundred and ten malaria-infected males with a mean 
age of 27.2 ± 17.5 years were studied. Twenty-nine % of 
patients were children below 17 years of age. The blood 
donors were young males of mean age 27  ±  7.0  years 
(range 17–52).
Clinical details
Clinical details were available for only 48 malaria patients 
(7 children and 41 adults) who were hospitalized. Signifi-
cant clinical findings included fever (n = 110, 100%), sple-
nomegaly (n = 13, 27%) and pulmonary oedema (n = 3). 
Six adults demonstrated complications like cerebral 
malaria (n = 3), respiratory failure (n = 2) and renal fail-
ure (n = 1). Mean stay (in days) in hospital and intensive 
care was 4.38 ±  4.33 and 0.89 ±  2.99  days respectively. 
No mortality was observed in any patient. Treatment 
included artemisinin (n =  4), doxycycline (n =  8), qui-
nine (n = 4), and combination of anti-malarial in rest of 
the patients. Blood donors recruited in the study had no 
history of malaria in past 3 years. Two patients carrying 
G6PD mutation did not show complicated malaria and 
received artemisinin plus doxycycline and quinine.
Laboratory findings
Laboratory details were available for all malaria patients 
(n  =  110). Eighty-two percent patients were anaemic, 
14.5% were severely anaemic (with haemoglobin  <  7  g/
dL), 66% patients had thrombocytopaenia while 12% 
were leucopaenic. Twenty patients had haemoglobinu-
ria as reported in urine analysis. Laboratory parameters 
with respect to age group are summarized in Table  1). 
Relatively low platelets, more parasitaemia and higher 
creatinine were observed in adults compared to children. 
Blood donors recruited in the study were negative for 
ICT malaria test and had haemoglobin above 12.5  g/dL 
as per the blood bank policy. G6PD assay was not per-
formed in any individual.
Molecular studies
G6PD 563c.C>T was detected in four of 110 patients 
with falciparum malaria and in two of 100 healthy blood 
donors. Cumulative allelic frequency for G6PD 563c.
C>T was 0.0273 detected in 6 of 220 X-chromosomes 
(Table 2). There were two pediatric (age 5 and 12 years) 
and two adult patients (age 33 and 36  years) who were 
identified carrying G6PD 563c.C>T. Mean (±  SD) hae-
moglobin, median (IQR) platelet and median (IQR) 
parasite count in G6PD-deficient malaria-patients were 
8.9 ± 0.9 g/dL, 124 × 109/L (IQR 32, 171) and 57,920/μL 
of blood (IQR 12,920, 540,000), respectively.
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Discussion
This study showed an allelic frequency of 3.6% for G6PD-
Med in subjects infected with malaria in Southern Paki-
stan and 2.8% in all tested individuals. This is lower than 
average allelic frequency reports for G6PD deficiency 
from various regions of Pakistan. But considering that 
only one G6PD mutation (G6PD 563c.C>T) was looked 
for, we would have captured 80% of the G6PDd preva-
lence. Other G6PD variants reported from Pakistan 
were G6PD Orissa and Chatham [9], for which gene-pri-
maquine interaction is not known [12]. Literature review 
showed that there were 15 national surveys [13–27] with 
an average of 200 individuals per survey. Studies done so 
far from 1966 to date showed a frequency of 3.9% (range 
1.1–8.5%) for G6PDd in Northern Pakistan. Highest fre-
quency was observed in Pashtun males as 5.3% compared 
to Punjabis (3.3%), Sindhis (2.7%) and Mohajir (2.2%) 
males (Table  3). This G6PDd frequency is comparable 
with global G6PD map computed by Howes et al. in 2012 
[28]. The data for females was not analyzed as they were 
underrepresented in all studies.
Gething et  al. in 2011 estimated P. falciparum trans-
mission globally through mathematical modeling [29]. 
Accordingly, 1.13 and 1.44 billion people, respectively, 
were at risk of stable and unstable malaria worldwide 
in 2010. In this model, Punjab, Gligit Baltistan, some 
areas of Baluchistan and Sindh were depicted as having 
a low annual incidence of < 1 malaria case in a popula-
tion of 10,000 [30]. Khyber Pakhtunkhwa (KPK) and 
majority of Sindh were evaluated to have stable malaria 
transmission having a prevalence of  >  1:10,000 popula-
tion [30]. There is also high transmission of malaria in 
districts bordering Afghanistan and Iran that carry 
37% of national malaria burden with an annual inci-
dence exceeding 4.5 cases/1000 population [31]. Inter-
estingly, largest number studies to date are from KPK 
which show a high incidence of G6PD deficiency with 
an allele frequency of 0.241. This indirectly indicates 
that G6PD deficiency does not provide absolute immu-
nity against infection with P. falciparum. This was 
observed in the current study as well, as four of 110 
patients with falciparum malaria had G6PD 563c.C>T 
mutation and were not immune to malaria. Moreover, 
the G6PDd malaria patients had high parasite burden 
of 152,821.00  ±  259,297.01/μL in this study. In con-
trast, Guindo et  al. reported protective effect of G6PD 
A-type in African males against falciparum infection 
[6]. The variance may be due to predominance of G6PD 
563c.C>T in Pakistani population that may have differ-
ent effect on P. falciparum survival than that observed 
in G6PD A-African population. More studies are needed 
on the immunity (if any) conferred by G6PD 563c.C>T 
Table 1 Demographic, clinical and laboratory data for paediatric and adult patients with malaria (n = 110)
Parameters Paediatric group Adult group All patients
n 32 78 110
Age in years (mean ± SD) 6.9 ± 4.9 35.2 ± 13.9 27.0 ± 17.6
Haemoglobin g/dL (mean ± SD) 9.2 ± 2.7 10.7 ± 2.8 10.3 ± 2.8
White cell count × 109/L(median; IQR) 8.0 (5.9–9.3) 6.9 (4.8-10.8) 7.3 (5.0–10.0)
Platelet count × 109/L(median; IQR) 130 (105–255) 109 (55–151) 120 (59–183)
Parasite count/µL (median; IQR) 2916 (800–26,180) 15,740 (4185–59,290) 9960 (2360–48,740)
Alanine aminotransferase IU/L (median; IQR) 47 (42–71) 43.9 (31.0–53.0) 44.7 (32.53)
Serum creatinine (mg/dL) (median; IQR) 0.9 (0.6–1.2) 1.3 (1.0–1.6) 1.2 (0.9–1.4)
Table 2 G6PD c.563C>T allele frequency in  the study 
group (n = 210)
Subjects n G6PD563C>T Allelic frequency
Healthy donors 100 02 0.0200
Malaria patients 110 04 0.0364
All individuals 210 06 0.0285
Table 3 Allele frequency for  G6PDd in  multi-ethnic males 
in Pakistan [13–25, 27]
NA not available
Ethnic groups Male
N (%)
Deficient male
N (% of total)
Allelic frequency
Pashtun 1321 (17.0) 84 (6.4) 0.0636
Punjabi 3227 (43.5) 71 (2.2) 0.0220
Sindhi 397 (5.4) 11 (2.8) 0.0277
Baloch NA NA NA
Bengali 146 (2.0) 2 (1.4) 0.0137
Kashmiri 460 (6.2) 5 (1.1) 0.0109
Mohajir 45 (0.6) 1 (2.2) 0.0222
Miscellaneous 1817 (24.5) 115 (6.3) 0.0633
Total 7750 (100) 592 (3.9) 0.0390
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against P. falciparum in hemizygous males and heterozy-
gous females.
G6PD 563c.C>T is highly prevalent in West Asia 
including Pakistan [12]. This mutation causes severe hae-
molysis when challenged with primaquine. This may be 
life threatening leading to renal failure and death [12]. 
The effect of primaquine therapy on females who are 
carriers for this mutation is not known. Currently, safe 
alternatives for primaquine therapy are not available [3]. 
Therefore, mandatory G6PD testing is the only option 
for Pakistan before intervening for malaria eradication 
with primaquine. More studies are needed on genome 
sequencing for identifying G6PD variants in Pakistan. 
This information can be used in developing an in-house 
point-of-care testing device for phenotype-genotype 
analysis and correct mapping of G6PDd. It can be incor-
porated in the mandatory neonatal screening as is avail-
able for hypothyroidism in Pakistan.
Strength and limitations
The study provides a database for G6PD 563c.C>T vari-
ance in Southern Pakistan demonstrating presence of this 
variant in patients suffering from malaria. The study had 
certain limitations as mutational analysis in females and 
in patients suffering from vivax malaria was not done. 
G6PD assay was not done hence the true prevalence of 
G6PD deficiency was underestimated. Moreover, other 
G6PD mutations except G6PD 563c.C>T were not iden-
tified. However the study did provide a snapshot for the 
presence of severe form of G6PD deficiency in Southern 
Pakistan.
Conclusions and recommendations
Cumulative allelic frequency for G6PD 563c.C>T was 
0.0273 detected in 6 of 220 X-chromosomes. The allele 
frequency is in line with previously reported data from 
Pakistan. This study advocates mandatory need for 
G6PD testing prior to anti-malarial intervention with 
primaquine therapy. Escalating doses of primaquine in 
patients with G6PD deficiency needs to be addressed in 
future studies.
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